CUE

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Lin Shao-LeeDirector, Officer: Chief Executive Officer $500k45.5k shares BuyJun 1, 2026 $500.0K45.5k shares $11.00 --
Lin Shao-LeeDirector, Officer: Chief Executive Officer $9190.9k shares BuyJun 1, 2026 $9190.9k shares $0.001 --
Meehan Viola MongDirector $36k1.6k shares Grant / ExerciseMay 30, 2026 $35.6K1.6k shares $21.90 --
Lin Shao-LeeDirector, Officer: CHIEF EXECUTIVE OFFICER $20M655.1k shares Grant / ExerciseMay 3, 2026 $19.9M655.1k shares $30.42 --
Lin Shao-LeeDirector, Officer: CHIEF EXECUTIVE OFFICER --327.5k shares Grant / ExerciseMay 3, 2026 Disclosure amount unavailable327.5k shares -- --
Warren LucindaCHIEF BUSINESS OFFICER $73k250k shares Grant / ExerciseApr 9, 2026 $72.5K250k shares $0.29 --

News

globenewswire.comCue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolutionglobenewswire.comJun 2

globenewswire.comCue Biopharma to Present at the 2026 Jefferies Global Healthcare Conferenceglobenewswire.comMay 21

globenewswire.comCue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developmentsglobenewswire.comMay 14

globenewswire.comCue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comMay 7

globenewswire.comCue Biopharma Announces $30 Million Private Placementglobenewswire.comApr 30

Trade CUE

About Cue Biopharma, Inc.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.

CEO: Lucinda Warren
IPO Date: Jan 2, 2018

Market Data

Open: $30.13
High: $31.57
Low: $30.02
Volume: 14K
52W High: $41.42
52W Low: $4.98

Valuation

Market Cap: $79M
Enterprise Value: $66M

Financials

Free Cash Flow: $-22M
Revenue: $27M
Net Income: $-27M
Cash: $27M
Debt: $4.2M

Events

EarningsAug 18

EPS est. -1.69